Physician profile
Ellen E Urrutia
NPI 1629046388
$2,673.31
in general payments reported to CMS, 2019-2025
14 companies · $284 in 2025
The $284 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.22 · 2020: $274 · 2021: $153 · 2022: $655 · 2023: $697 · 2024: $559 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $1,121.13 | 2022-2025 | Barostim Neo System |
| Boston Scientific Corporation | $485.85 | 2019-2025 | Cds - Mct/Cem Monitoring |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $207.62 | 2021-2024 | Lifevest |
| Amgen INC. | $180.13 | 2023-2024 | Repatha |
| Pfizer INC. | $161.14 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $118.31 | 2020 | |
| Abiomed | $111.96 | 2020 | |
| Novartis Pharmaceuticals Corporation | $72.55 | 2019-2024 | |
| Heartflow, INC. | $62.99 | 2023-2025 | Ffrct |
| Itamar Medical INC | $49.07 | 2023 | Watchpatone |
| Biotronik INC. | $48.46 | 2025 | Acticor 7 Vr-T Dx |
| Astrazeneca Pharmaceuticals LP | $26.29 | 2023 | Farxiga |
| Amarin Pharma, INC. | $14.69 | 2019 | |
| Allergan, INC. | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Urrutia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.